Wyniki wyszukiwania

1

Modulatory effect of the Euro-Lupus low-dose intravenous cyclophosphamide regimen on circulating immune cells in systemic lupus erythematosus

100%

Gabcova G., Horak P., Mikulkova Z., Skacelova M., Zehnalova S., Smrzova A., Petrackova A., Mrazek F., Kriegova E.

Archivum Immunologiae et Therapiae Experimentalis

|

2019

|

tom 67

|

nr 6

2

Safety and efficacy of intravenous cyclophosphamide pulse therapy in therapy refractory Crohn's disease patients

100%

Hirschmann S., Atreya R., Englbrecht M., Neurath M. F.

Journal of Physiology and Pharmacology

|

2017

|

tom 68

|

nr 1

3

TFX modulates the immunosuppressive effect of cyclophosphamide on antibody production in mice

100%

Paczek L., Gaciong Z., Gorski A., Lagodzinski Z., Brzezny M.

Archivum Immunologiae et Therapiae Experimentalis

|

1989

|

tom 37

|

nr 3-4

4

Evaluation of selected protein biomarkers of renal function in rats with an experimental model of acute cyclophosphamide-induced cystitis treated with N-acetylcysteine

100%

Dobrek L., Nalik-Iwaniak K., Kopanska M., Arent Z., Thor P. J.

Journal of Physiology and Pharmacology

|

2019

|

tom 70

|

nr 5

5

Immunogenic and nondividing mafosfamide-treated L 1210 cells - comparison of lines resistant and nonresistant to cyclophosphamide

100%

Kawalec M., Hoser G., Skorski T., Kawiak J.

Folia Histochemica et Cytobiologica

|

1993

|

tom 31

|

nr 2

6

Effect of blood transfusion and cyclophosphamide on cardiac allograft survival in sensitized mice

100%

Lasek W., Sora M., Jakobisiak M.

Archivum Immunologiae et Therapiae Experimentalis

|

1994

|

tom 42

|

nr 5-6

7

Contrasting effect of oral and intravenous cyclophosphamide treatment on phenotypes of human peripheral blood lymphocytes

100%

Lacki J. K., Mackiewicz S. H., Wiktorowicz K. E.

Archivum Immunologiae et Therapiae Experimentalis

|

1994

|

tom 42

|

nr 4

8

Combination of vasostatin gene therapy with cyclophosphamide inhibits growth of B16[F10] melanoma tumours

100%

Jazowiecka-Rakus J., Jarosz M., Szala S.

Acta Biochimica Polonica

|

2006

|

tom 53

|

nr 1

Angiogenesis, i.e. formation of new blood vessels out of pre-existing capillaries, is essential to the development of tumour vasculature. The discovery of specific antiangiogenic inhibitors has important therapeutic implications for the development of novel cancer treatments. Vasostatin, the N-terminal domain of calreticulin, is a potent endogenous inhibitor of angiogenesis and tumour growth. In our study, using B16(F10) murine melanoma model and electroporation we attempted intramuscular transfer of human vasostatin gene. The gene therapy was combined with antiangiogenic drug dosing schedule of a known chemotherapeutic (cyclophosphamide). The combination of vasostatin gene therapy and cyclophosphamide administration improved therapeutic effects in melanoma tumours. We observed both significant inhibition of tumour growth and extended survival of treated mice. To our knowledge, this is one of the first reports showing antitumour efficacy of electroporation-mediated vasostatin gene therapy combined with antiangiogenic chemotherapy.

9

Experimental infections of anal glands of Didelphis marsupialis by Trypanosoma cruzi and the effects of immunosuppressive treatment

100%

Herrera L., Urdaneta-Morales S.

Acta Parasitologica

|

2001

|

tom 46

|

nr 3

10

Strain-dependent differences in mutagenicity and genotoxicity of cyclophosphamide in mice

100%

Ejchart A., Koziorowska J.

Acta Biochimica Polonica

|

1993

|

tom 40

|

nr 1

11

Effect of alkylating drugs on rat cerebellum

84%

Maslinska D.

Folia Histochemica et Cytobiologica

|

1986

|

tom 24

|

nr 1

12

Vasostatin increases oxygenation of B16-F10 melanoma tumors and raises therapeutic efficacy of cyclophosphamide

84%

Cichon T., Jarosz M., Smolarczyk R., Ogorek B., Matuszczak S., Wagner M., Mitrus I., Sochanik A., Jazowiecka-Rakus J., Szala S.

Acta Biochimica Polonica

|

2012

|

tom 59

|

nr 3

One of the preconditions of effective anticancer therapy is efficient transfer of the therapeutic agent (chemotherapeutic) to tumor cells. Fundamental barriers making drug delivery and action difficult include underoxygenation, elevated interstitial pressure, poor and abnormal tumor blood vascular network and acidic tumor milieu. In this study we aimed at developing an optimized scheme of administering a combination of an angiogenesis-inhibiting drug (vasostatin) and a chemotherapeutic (cyclophosphamide) in the therapeutic treatment of mice bearing experimental B16-F10 melanoma tumors. We report that the strongest tumor growth inhibition was observed in mice that received two, three or four vasostatin doses in combination with one injection of cyclophosphamide (i.e., V2 + CTX, V3 + CTX or V4 + CTX schemes). Double administration of vasostatin increases oxygenation of B16-F10 tumors. On the other hand, its five-fold administration lowers tumor oxygenation, breaks down tumor vascular network (increasing hypoxia) and leads in consequence to death of cancer cells and appearance of necrotic areas in the tumor. A decreased cyclophosphamide dose in combination with two doses of vasostatin (V2 + CTX scheme) inhibits tumor growth similarly to a larger dose of cyclophosphamide alone.

13

Potentiation of cyclophosphamide-induced enhancement of experimental metastasis by splenectomy

84%

Strzadala L., Rak J., Ziolo E., Kusnierczyk H., Radzikowski C.

Archivum Immunologiae et Therapiae Experimentalis

|

1989

|

tom 37

|

nr 3-4

14

Effects of cytostatics on the selected parameters of cell-mediated immunity in dogs

84%

Brodzki P., Wrona Z., Piech T., Brodzki A.

Bulletin of the Veterinary Institute in Puławy

|

2011

|

tom 55

|

nr 1

The aim of the study was to assess the effects of tamoxifen and cyclophosphamide on the selected cell-mediated immunity parameters in dogs. The study included 18 dogs aged 5-10 years. The experimental group consisted of 12 animals with neoplastic lesions classified as the first or second staging group (according to the WHO TMN classification). This group was divided into two subgroups: I - six dogs receiving oral tamoxifen, and II - six dogs with cyclophosphamide administered orally. The control group included six healthy dogs. The blood was sampled from the saphenous access vein two times at 14-d intervals before the drug administration, three times every 7 d during administration, and two times every 14 d after completion of the therapy. The basic blood tests were carried out and the subpopulations of TCD4+ and TCD8+ lymphocytes, and phagocytic activity of granulocytes and monocytes were determined using flow cytometry. It was found that tamoxifen induced a marked increase in WBC and neutrophil counts, increased phagocytic activity of monocytes, and changed the CD4+:CD8+ ratio (in favour of cytotoxic lymphocyte subpopulation). These findings indicated the stimulation of cell-mediated immunity mechanisms. Cyclophosphamide caused a substantial decrease in the overall leukocyte pool and reduced the percentage of cells activated for phagocytosis, both neutrophils and monocytes even after completion of its administration, which proves its immunosuppressive effects.

15

The effect of hyperosmolar stimuli and cyclophosphamide on the culture of normal rat urothelial cells in vitro

84%

Juszczak K., Kaszuba-Zwoinska J., Chorobik P., Ziomber A., Thor P. J.

Cellular and Molecular Biology Letters

|

2012

|

tom 17

|

nr 2

Highly concentrated urine may induce a harmful effect on the urinary bladder. Therefore, we considered osmolarity of the urine as a basic pathomechanism of mucosal damage. The influence of both cyclophosphamide (CYP) and hyperosmolar stimuli (HS) on the urothelium are not well described. The purpose was to evaluate the effect of CYP and HS on rat urothelial cultured cells (RUCC). 15 Wistar rats were used for RUCC preparation. RUCC were exposed to HS (2080 and 3222 mOsm/l NaCl) for 15 min and CYP (1 mg/ml) for 4 hrs. APC-labelled annexin V was used to quantitatively determine the percentage of apoptotic cells and propidium iodide (PI) as a standard flow cytometric viability probe to distinguish necrotic cells from viable ones. Annexin V-APC (+), annexin V-APC and PI (+), and PI (+) cells were analysed as apoptotic, dead, and necrotic cells, respectively. The results were presented in percentage values. The flow cytometric analysis was done on a FACSCalibur Flow Cytometer using Cell-Quest software. Treatment with 2080 and 3222 mOsm/l HS resulted in 23.7 ± 3.9% and 26.0 ± 1.5% apoptotic cells, respectively, 14.3 ± 1.4% and 19.4 ± 2.7% necrotic cells, respectively and 60.5 ± 1.4% and 48.6 ± 5.3% dead cells, respectively. The effect of CYP on RUCC was similar to the effect of HS. After CYP the apoptotic and necrotic cells were 23.1 ± 0.3% and 17.9 ± 7.4%, respectively. The percentage of dead cells was 57.7 ± 10.8%. CYP and HS induced apoptosis and necrosis in RUCC. 3222 mOsm/l HS had the most harmful effect based on the percentage of necrotic and apoptotic cells.

16

Current approaches for the treatment of autoimmune hemolytic anemia

84%

Jaime-Perez J. C., Rodriguez-Martinez M., Gomez-de-Leon A., Tarin-Arzaga L., Gomez-Almaguer D.

Archivum Immunologiae et Therapiae Experimentalis

|

2013

|

tom 61

|

nr 5

17

Aldehyde dehydrogenase isoenzymes in tumours - assay with possible prognostic value for oxazaphosphorine chemotherapy

84%

Wroczynski P., Laskowska A., Wierzchowski J., Szubert A., Polanski J., Slowiaczek M.

Acta Biochimica Polonica

|

1998

|

tom 45

|

nr 1

A novel fluorimetric assay, allowing independent measurement of the activities of two principal cytosolic forms of human aldehyde dehydrogenase, ALDH-1 and ALDH-3 (known as a tumour-associated ALDH) was applied to estimate the activities of these isoenzymes in human liver and thyroid tumours. The assay is based on two artificial substrates, 6-methoxy-2-naphthaldehyde (MONAL-62) and 7-methoxy-1-naphthaldehyde (MONAL-71), exhibiting excellent substrate properties toward various forms of human ALDH (see Wierzchowski et al., 1997, Anal. Biochem. 245, 69-78). We have found significant differences in ALDH activities between malignant and non-malignant tissue fragments, particularly in cancerous livers. Out of 16 tumours examined, only 4 exhibited ALDH-1 activities comparable to that found in the tumour-free tissue (0.5-2.5 U/g), while in the remaining 12 this activity was at least 10-fold lower. The ALDH-3 activity was detectable in about 40% of both tumour and tumour-free liver samples (maximum value 1.5 U/g). Comparison of 13 pathological thyroid fragments revealed ALDH activities in the range of 0.02 to 0.35 U/g, with two malignant samples showing activities of 0.27 and 0.18 U/g. Both substrate specificity and kinetic behaviour of the thyroid ALDH (Km values for the fluorogenic naphthaldehydes as well as propanal inhibition profile) were similar to those of the purified ALDH-1. In 5 thyroid samples traces of ALDH-3 activity was detected, using MONAL-62 and NADP+ as substrates (maximum value 0.04 U/g). Possible prognostic value of the foregoing measurements for cyclophosphamide chemotherapy is discussed.

18

Combination of vasostatin and cyclophosphamide in the therapy of murine melanoma tumors

84%

Jazowiecka-Rakus J., Jarosz M., Kozlowska D., Sochanik A., Szala S.

Acta Biochimica Polonica

|

2007

|

tom 54

|

nr 1

Growth of tumors is strongly dependent upon supply of nutrients and oxygen by de novo formed blood vessels. Inhibiting angiogenesis suppresses growth of primary tumors as well and affects development of metastases. We demonstrate that recombinant MBP/vasostatin fusion protein inhibits proliferation of endothelial cells in vitro. The therapeutic usefulness of such intratumorally delivered recombinant protein was then assessed by investigating its ability to inhibit growth of experimental murine melanomas. In the model of B16-F10 melanoma the MBP/vasostatin construct significantly delayed tumor growth and prolonged survival of treated mice. A combination therapy involving MBP/vasostatin construct and cyclophosphamide was even more effective and led to further inhibition of the tumor growth and extended survival. We show that such combination might be useful in the clinical setting, especially to treat tumors which have already formed microvessel networks.

19

Wegener's granulomatosis - autoimmunity to neutrophil proteinase 3

84%

Watorek E., Boratynska M., Klinger M.

Archivum Immunologiae et Therapiae Experimentalis

|

2003

|

tom 51

|

nr 3

20

Influence of 2-chloro-2'-deoxyadenosine alone and in combination with cyclophosphamide or methotrexate on murine leukemia L1210

84%

Gora-Tybor J., Robak T., Warzocha K., Grieb P.

Archivum Immunologiae et Therapiae Experimentalis

|

1994

|

tom 42

|

nr 1

Ograniczanie wyników

Modulatory effect of the Euro-Lupus low-dose intravenous cyclophosphamide regimen on circulating immune cells in systemic lupus erythematosus

Safety and efficacy of intravenous cyclophosphamide pulse therapy in therapy refractory Crohn's disease patients

TFX modulates the immunosuppressive effect of cyclophosphamide on antibody production in mice

Evaluation of selected protein biomarkers of renal function in rats with an experimental model of acute cyclophosphamide-induced cystitis treated with N-acetylcysteine

Immunogenic and nondividing mafosfamide-treated L 1210 cells - comparison of lines resistant and nonresistant to cyclophosphamide

Effect of blood transfusion and cyclophosphamide on cardiac allograft survival in sensitized mice

Contrasting effect of oral and intravenous cyclophosphamide treatment on phenotypes of human peripheral blood lymphocytes

Combination of vasostatin gene therapy with cyclophosphamide inhibits growth of B16[F10] melanoma tumours

Experimental infections of anal glands of Didelphis marsupialis by Trypanosoma cruzi and the effects of immunosuppressive treatment

Strain-dependent differences in mutagenicity and genotoxicity of cyclophosphamide in mice

Effect of alkylating drugs on rat cerebellum

Vasostatin increases oxygenation of B16-F10 melanoma tumors and raises therapeutic efficacy of cyclophosphamide

Potentiation of cyclophosphamide-induced enhancement of experimental metastasis by splenectomy

Effects of cytostatics on the selected parameters of cell-mediated immunity in dogs

The effect of hyperosmolar stimuli and cyclophosphamide on the culture of normal rat urothelial cells in vitro

Current approaches for the treatment of autoimmune hemolytic anemia

Aldehyde dehydrogenase isoenzymes in tumours - assay with possible prognostic value for oxazaphosphorine chemotherapy